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Gene delivery using calcium phosphate nanoparticles:
Optimization of the transfection process and the effects of citrate
and poly(l-lysine) as additives
Mohammed A. Khan, Victoria M. Wu, Shreya Ghosh, Vuk Uskoković
Advanced Materials and Nanobiotechnology Laboratory, Department of Bioengineering, University of Illinois,
Chicago, IL 60607-7052, USA

Abstract Despite the long history of nanoparticulate calcium phosphate (CaP) as a non-viral
transfection agent, there has been limited success in attempts to optimize its properties for
transfection comparable in efficiency to that of viral vectors. Here we focus on the optimization
of: (a) CaP nanoparticle precipitation conditions, predominantly supersaturation and Ca/P molar
ratios; (b) transfection conditions, mainly the concentrations of the carrier and plasmid DNA; (c)
the presence of surface additives, including citrate anion and cationic poly(L-lysine) (PLL). CaP
nanoparticles significantly improved transfection with plasmid DNA encoding enhanced green
fluorescent protein (eGFP) in pre-osteoblastic MC3T3-E1 cells compared to a commercial nonviral carrier. At the same time they elicited significantly lesser cytotoxicity than the commercial
carrier. Plasmid DNA acted as a nucleation promoter, decreasing the nucleation lag time of
metastable CaP solutions and leading to a higher rate of nucleation and a lower size of the
precipitated particles. The degree of supersaturation (DS) of 15 was found to be more optimal for
transfection than that of 12.5 or 17.5 and higher. Because CaP particles precipitated at DS 15
were spherical, while DS 17.5 and 21 yielded acicular particles, it was concluded that spherical
particle morphologies were more conducive to transfection than the anisotropic ones. Even
though the yield at DS 15 was 10 and 100 times lower than that at DS 17.5 and 21, respectively,
transfection rates were higher using CaP nanoparticle colloids prepared at DS 15 than using
those made at higher or lower DS, indicating that the right particle morphology can outweigh the
difference in the amount of the carrier, even when this difference is close to 100x. In contrast to
the commercial carrier, the concentration of CaP-pDNA delivered to the cells was directly
proportional to the transfection rate. Osteosarcoma K7M2 cells were four times more easily
transfectable with CaP nanoparticles than the MC3T3-E1 cells. The addition of citrate increased
the transfection rate at lower concentrations; however, a complete redispersal of CaP-pDNA
nanoparticles at higher concentrations of citrate coincided with a complete diminishment of
transfection, implying the benefits of partial aggregation of CaP nanoparticles carrying pDNA. In
contrast, PLL delayed transfection initially, but enhanced it at longer time points (≥ 96 h),
leading to the conclusion that both citrate and PLL could exert positive effects on transfection:
citrate if added at low concentrations and PLL to extend transfection over longer periods of time.
Keywords: Calcium phosphate; Citrate; Confocal microscopy; Gene delivery; Hydroxyapatite;
Immunofluorescence; Nanoparticles; Plasmid DNA; Poly(L-lysine); Transfection.
1. Introduction
Transfection is the process of introducing exogenous genetic material into the cell and is
extensively investigated due to its potential therapeutic uses [1]. Traditionally viral vectors are
used to ensure high transfection efficiencies; however, risks associated with viral gene delivery

include the elicitation of immunogenic responses, toxicity, insertional mutagenesis and the
limited amount of DNA transportable by the carrier [2]. To overcome these issues, non-viral
methods have been developed to artificially deliver DNA to cells, including direct injection [3],
electroporation [4], and the use of particulate carriers, e.g., polymeric particles [5], cationic
polymeric micelles [6], ionic lipids [7], and inorganic particles, the most prospective of which
have been calcium phosphates (CaP) [8]–[10].
The use of CaP as a transfection agent is justified by the fact that it is inexpensive,
nontoxic, biocompatible, bioactive, easily synthesizable and degradable in the early lysosome
[11]. CaP is also a component of all hard tissues in the body and will degrade to ions present in
all cells and extracellular fluids, which also makes it a safe and biocompatible material for
intracellular delivery. The first major advantage of CaP over other inorganic particles for this
therapeutic application comes from its high loading capacity. Thanks to the highly charged ionic
surface species (Ca2+ and PO43-), CaP can bind to an array of organics. Alternation between Ca2+
and PO43- species also endows CaP with a large surface charge density, making it similar to viral
capsids, which owe their penetrability of the cell membrane to one such charge density that is
variable in sign on the atomic scale but also comparable in magnitude to that of DNA [12].
Secondly, DNA-loaded CaP particles (CaP-DNA) are taken up by the cells through caveolaeand clathrin-mediated endocytoses [13]. Once internalized, CaP-DNA is expected to remain
stable in the early through late endosome until its transition to the acidic lysosome (pH ~4) [14],
at which point CaP particles start to dissolve. The release of constituent ions raises the osmotic
pressure inside the lysosome, causing the vesicle to burst and release the nucleic acid cargo into
the cytosol before its premature degradation in the late lysosome[11], [13].
Nanoparticles have been investigated as the most prospective non-viral transfection
carriers for gene therapies. However, nanoparticle aggregation can significantly reduce the
transfection efficiencies [15]–[17]. Therefore, we wanted to test if citrate, a strong dispersant
[18], would increase the efficiency of transfection by stabilizing CaP particles in suspension. The
great majority (~ 80 %) of citrate ions resides in bone, where they account for 5.5 wt% content of
its organic component or ~ 1.6 wt% overall [19] and where they coat the plate-shaped CaP
crystals, facilitating their dispersal within the collagenous matrix of bone [20]. Their positive
effect on necrotic bone regeneration when delivered in a polymeric form and in combination
with CaP has also been noted [21]. The rationale for the use of poly(L-lysine) (PLL) is
following: since cationic polymers were previously used as transfection agents [22]–[24] and
viral vectors are highly effective in part due to the positively charged glycosidic moieties of the
capsid shell, we wished to determine if adding a positively charged polypeptide to CaP would
improve the transfection rate. PLL has been previously used as a functional surface coating [25]
and to deliver drugs [26], [27] and DNA [22]–[24]. Moreover, PLL is capable of disrupting the
cell membrane[22], allowing for an easier passage of pDNA-loaded particles into the cytoplasm.
2. Materials and methods
2.1. Synthesis of CaP-pDNA, CaP-pDNA-PLL and CaP-pDNA-citrate particles
Two precursor solutions were made in identical volumes, one containing 250 mM CaCl2
(Sigma-Aldrich) and 50 µg/ml plasmid DNA (pDNA) encoding for enhanced green fluorescent
protein (eGFP) and the other one containing varying amounts of NaH2PO4 (Sigma-Aldrich), 140
mM NaCl (Sigma-Aldrich) and 50 mM HEPES (pKa =7.5, Life Technologies). pH of the

NaH2PO4 solution was set to 7 unless noted otherwise. pDNA did not affect pH in the system.
The precursor solution containing CaCl2 was added drop-wise to the one containing NaH2PO4,
which was being continuously vortexed at 1000 rpm. For synthesis of CaP-pDNA particles
combined with PLL or citrate, the CaCl2 solution contained different concentrations of either
PLL (70 – 150 kDa, Sigma-Aldrich) or citric acid monohydrate (Fisher-Scientific).
The degrees of supersaturation (DS) of solutions precipitating CaP-DNA were calculated
using an algorithm based on Debye-Hückel equation[28]:
DS = pKsp – pQ

(Eq.1)

where Q is the ionic activity product of the solution, and Ksp is the solubility product of the CaP
phase precipitated in this study, hydroxyapatite (Ca5(PO4)3OH, HAp), the negative logarithm of
which was taken as equal to 58.65. Activity coefficients were calculated through logγ = - Azi2 /
(I1/2 + Bai), where zi is the charge number of ion species i, I is the ionic strength of the solution,
A is a temperature-dependent constant equal to 0.5115 at 25 oC. B and ai are, like A, constants
depending on temperature, dielectric constant of the solution and Debye screening length; ai = 6
x 10-8 for Ca2+; 9 x 10-8 for H+; and 4 x 10-8 for HxPO4x-3/CaH2xPO42x-1 ions. Appropriate
dissociation constants for H2O, HxPO4x-3, HxCO3x-2 and HF and association constants for
CaHxPO4x-1, CaHxCO3x and Ca---OH were taken into account as functions of pH[28]. Table 1
summarizes the different ionic concentrations used to obtain DS of solutions precipitating CaPDNA nanoparticles at 20oC and the background ionic strength of 140 mM. Different DS values
were obtained by varying [HxPO4x-3] and keeping [Ca2+] constant. Ca/P molar ratio was altered
by maintaining constant [Ca2+] to ensure the approximate similarity of CaP yield under different
DS conditions.
Table 1. Different degrees of supersaturation (DS), ionic concentrations, pDNA concentrations, pDNA-CaP binding
efficiencies, yield of the solid phase, crystallinity of phases (HAp = hydroxyapatite; DCP = brushite), and initial and
final pH values of the solutions from which CaP-pDNA nanoparticles were precipitated.
DS

Initial
[Ca2+]
(mM)

Initial
[HxPO4x-3]
(mM)

Ca/P molar
ratio

Initial
[pDNA]
(µg/ml)

pDNACaP
binding
efficienc
y (%)
25.36 ±
6.56

pH of the
precipitating
solution

pH of
the
final
solution

Yield
(g/dm3)

Average
crystallite
size (nm)

12.5

125

0.1

1.25 x 103

25

7

7

n.a.

n.a.

15

125

0.7

178

25

93.3
0.6

±

7

7

0.5

14.5
(HAp)

17.5

125

4.5

27.8

25

99.47
0.92

±

7

6.6

6

15.4
(HAp)

21

125

30

4.2

25

97.07
0.61

±

7.3

5.8

42

11.9
(HAp) &
55.4
(DCP)

2.2. Characterization of CaP-pDNA, CaP-pDNA-PLL and CaP-pDNA-citrate
Scanning Electron Microscopy (SEM) was performed on a JEOL JSM 6320F-FESEM
operated at 1 - 4 kV voltage range and 8𝜇A beam current. ImageJ (NIH, Bethesda, MD) was
used to derive the particle size and aspect ratio histograms from SEM images. Zeta potential and
hydrodynamic diameters of particles in suspension were measured using a Zetasizer Nano-ZS
(Malvern) dynamic light scattering (DLS) device and the data were plotted as number
distributions to minimize for the effect of intense scattering from large entities. X-Ray
Diffraction (XRD) was carried out on a Bruker D2 Phaser diffractometer in 23 – 90 o 2θ range.
The Scherrer equation applied on the most intense reflections for a given phase in the 2θ range
used - (211) at 31.86 ° for HAp and (141) at 29.17 ° for brushite - was used to estimate the
average crystallite size from the diffraction peak half-widths in DIFFRAC.EVA software.
2.3. Binding of pDNA to CaP
Binding of pDNA to CaP particles was determined using a Nanodrop 2000
Spectrophotometer (Thermo Scientific). 500 μl of suspension containing CaP-pDNA, CaP-PLLpDNA or CaP-citrate-pDNA were centrifuged at 4 °C for 1 h at 14,000 rpm. The binding
efficiency was determined as the average of three independent measurements using the following
𝑝𝑝𝑝𝑝𝑡𝑡𝑡𝑡𝑡 −𝑝𝑝𝑝𝑝𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
, where B is the binding efficiency, pDNAtotal is the total
equation: 𝐵 =
𝑝𝑝𝑝𝑝
𝑡𝑡𝑡𝑡𝑡

amount of pDNA added to the system, and pDNAsupernantant is the amount of unbound pDNA in
the supernatant.
2.4.In vitro transfection studies

K7M2 murine osteosarcoma cells (ATCC) and MC3T3-E1 subclone 4 pre-osteoblastic
murine calvarial cells (ATCC) were cultured at 37°C and 5% CO2 in MEM-α (Gibco) and
DMEM (Gibco) media, respectively, with 10 % FBS and 1 % antibiotic-antimycotic (Gibco) to
prevent bacterial and fungal contamination. Cells were seeded at 5 x 104 cells/well in 24-well
plates and transfected 24 hours later with the addition of 1, 0.5 and 0.25 µg of eGFP plasmid
loaded onto CaP in suspension. Transfections were performed in triplicate and compared to
jetPRIME (Polyplus), a non-liposomal, polycationic commercial transfection agent used
according to manufacturer’s instructions. Fluorescence of expressed eGFP was measured using a
microplate reader (FLUOstar Omega, BMG LABTECH). The cells were excited at 485 nm and
the emissions were detected at 520 nm.
2.5. Immunofluorescent staining and confocal microscopy
Cells were fixed and stained 2 days post-transfection for nucleus, f-actin, eGFP, and CaP.
They were fixed for 5 minutes in 4 % paraformaldehyde (PFA) and washed 3 x 10 min in PBS.
Cells were blocked at room T for 1 h in blocking solution (2 % bovine serum albumin, 0.5 %
Triton-X in PBS). Cells were then incubated in rabbit anti-GFP 1:400 (AbCam) either overnight
at 4°C or for 1 h at room temperature. After primary incubation, cells were rinsed 3 x with PBS
and 1 x with OsteoImage wash buffer. Alexa 633 secondary antibody (1:400), Alexa Fluor 568
phalloidin (1:400) and OsteoImage reagent (1:100) were then added and incubated for 1 h at
room T. After incubation, cells were washed 3 x 5 min with OsteoImage wash buffer. Cells were

then incubated in NucBlue® Fixed Cell ReadyProbesTM reagent (Molecular Probes, Life
Technologies) for 5 - 10 min, rinsed in PBS and mounted.
2.6. MTT viability assay
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) solution was
prepared according to the manufacturer’s instructions (Vybrant® MTT Cell Proliferation Assay
Kit V-13154). Cells were plated and transfected as described in section 2.5. On days 2 and 5 the
assay was performed according to manufacturer’s instructions and absorbance was measured at
540 nm using a microplate reader (FLUOstar Omega, BMG LABTECH).
3. Results and discussion
3.1. Synthesis and characterization of CaP-pDNA, CaP-pDNA-PLL and CaP-pDNA-citrate
SEM images of bare CaP nanoparticles, CaP nanoparticles complexed with pDNA (CaPpDNA) and CaP-pDNA nanoparticles synthesized in the presence of citrate or PLL are displayed
in Fig.1. Bare CaP particles were spherical and narrowly dispersed at DS 15, having the average
size of 101.2 ± 17.3 nm. As DS increased, so did the proportion of elongated particles in the
precipitate. Particles synthesized at DS 17.5 were a mixture of spherical and acicular
morphologies, whereas those precipitated at DS 21 were completely acicular. Spherical CaP
particles prepared at DS 17.5 were 16.2 ± 3.7 nm in diameter and finer than those made at DS
15. The dimensions of acicular CaP particles prepared at DS 17.5 and 21 equaled 69.3 ± 7.4 x
7.5 ± 1.7 nm and 317 ± 53 x 26.6 ± 6.2 nm, respectively, with the corresponding aspect ratios of
9.2 and 11.9. Overall, CaP particles prepared at DS 17.5 were smaller than those prepared at DS
15. However, contrary to the theoretical expectations, which inversely relate the particle size and
supersaturation, particles made at DS 21 were larger than those made at DS 15 and DS 17.5. CaP
is typified by very high nucleation rates and is mostly immune to the direct correspondence
between DS and nucleation rate applicable to most other precipitates. The fact that CaP crystal
growth is largely controlled by particle aggregation, starting already at the sub-nanoscale, makes
the prediction of particle size from DS levels in the parent solution a difficult task.

Fig.1. (a) Scanning electron micrographs (a-d) and X-ray diffractograms (e) of CaP (a, e) and CaP-pDNA (b-d)
nanoparticles synthesized at different DS values. Reflections originating from HAp are denoted with “Δ”, while
those derived from brushite are denoted with “o”.

X-ray diffractograms demonstrate the monophasic nature of CaPs made at DS 15 and
17.5 and biphasic nature composed of HAp and brushite when made at DS 21 (Fig.1e).
Precipitation of HAp entails the capture of free hydroxyl ions from the solution and their binding
within the crystal lattice, while at this highest concentration of ionic growth units (DS 21) the
resulting drop in pH surpasses the buffering capacity of 50 mM HEPES set to pH 7.3. As a
result, the first phase to precipitate at DS 21 is HAp; brushite begins to precipitate instead of
HAp once the pH drops below ~ 6.8, resulting in a biphasic composition at the final pH of 6.3
(Table 1). Crystallinity of brushite was higher than that of HAp, the latter of which only mildly
decreased, from 15.4 to 11.9 nm, as DS increased from 17.5 to 21 (Table 1), this time going in
line with the aforementioned theoretical expectations. Still, the independence of crystallinity on
DS in the lower DS range reconfirms the complexity of precipitation pathways followed by CaP.
CaP particles prepared at DS 15 remained spherical and monodisperse when complexed
with pDNA, but their average size dropped from 101.2 ± 17.3 nm to 15.9 ± 4.4 nm. DNA can act
as a nucleation-promoting agent because of its triply charged phosphates that can complex Ca2+
from the solution. Consequently, DNA increased the nucleation rate and decreased the size of the
resulting particles. This was also evidenced by the ability of pDNA to decrease the nucleation lag
time in metastable CaP solutions; at DS 12, e.g., no precipitation was observed unless pDNA
was present, in which case the “crashing” of the solution was immediate. Despite the highly
charged nature of DNA, the tendency for primary CaP-pDNA particles to aggregate was obvious
from SEM images and was corroborated in the DLS analysis of CaP-pDNA colloids, which
resulted in the particle size of 233 ± 32 nm. The particle size distribution was bimodal, with
another peak, contributed to by ~ 12 % of particles in the system, being observed at 1.87 ± 0.43
μm, suggesting the coexistence of smaller and larger agglomerates. Elevating the pH to 11
deprotonated the surface to some extent and provided a better electrostatic charge repulsion,
dropping the particle size down to 191 ± 30 nm, though indicating that surface charge effects in
the absence of steric repulsion are not enough to disperse the primary particles despite their
comparatively high surface charge density. CaP-pDNA sols lacked the 10-nm size peak derived
from dissolved eGFP plasmids and detected in pure pDNA solutions, demonstrating that pDNA
was bound to CaP particles (Fig.2a). The addition of PLL did not significantly affect the particle
size, nor the bimodal distribution, with the major peak at 263 ± 65 nm and the minor one at 1.26
± 0.56 μm. PLL dispersions displayed the particle size maximum at 4.7 ± 1.3 nm, agreeing with
the estimate of the molecular size from the 70 – 150 kDa Mw range: 3.66 – 5.07 nm. The absence
of this peak in CaP-pDNA-PLL suggested no phase separation of polymeric and ceramic
components. The addition of citrate confirmed its role as a dispersant, as the size of both CaPpDNA and CaP decreased in direct proportion to its concentration. At low concentrations of
citrate, i.e., 10 and 100 μM, the agglomerates of CaP-pDNA are still present. However, at 1 mM,
the average particle size decreases down to 10 nm, suggesting the breaking of nanoparticle
agglomerates and the resuspension of nanoparticles in the medium. Citrate ions did not
redisperse CaP particles as well as CaP-pDNA ones, the reason being the partially dispersive role
that pDNA itself plays owing to its highly electrostatically charged nature. As a result, the
particle size observed following the addition of 10 mM citrate to CaP only was 170 nm,
compared to 28 nm for CaP-pDNA (Fig.2b).

Fig.2. (a) Particle size distributions of pDNA and PLL and of their combinations with CaP obtained using dynamic
light scattering at different pH values. (b) The effect of the concentration of citric acid on the average particle size of
CaP and CaP-pDNA in suspension.

Surface charge is an important determinant of cell permeability and the efficiency of
transfection [29]–[31]. As seen from Fig.3a, at pH 7, zeta (ζ) potential, which is directly
indicative of surface charge, was 9.7 ± 0.8 mV for pure CaP sol, - 33.5 ± 2.6 mV for pure pDNA
sol, and - 10.7 ± 0.8 mV for CaP-pDNA sol. Together with the absence of the pDNA size peak in
the DLS analysis of CaP-pDNA, these results confirm the formation of stable CaP-pDNA
complexes. Still, neither did the ζ potential of CaP nor that of CaP-pDNA reach the 15 – 30 mV
metastable range in which moderate colloidal stability could be ensured. With the ζ potential
below +- 15 mV, the particles are severely unstable and susceptible to aggregation, as evidenced
during the particle size analysis. With the addition of PLL to CaP-pDNA, ζ potential increased
due to the polycationic nature of the polymer, indicating its binding to the CaP-DNA complex.
Charge reversal from negative to positive takes place at ~ 7 ng/μl, whereas a surface saturation
point is reached at ~ 20 ng/μl of PLL, with no further increase in ζ potential occurring with the
addition of PLL. In contrast, as expected, the addition of anionic citrate maintains the negative
charge on the particles (Fig.3b). Any co-localization of citrate anions in the double charge layer
together with free hydroxyl groups does not induce charge imbalance and retains the negative
surface charge of the particle at the shear plane.

Fig.3. Zeta potential of pure CaP, pure DNA and CaP-DNA complexes at pH 7 (a). The effect of varying the
concentration of PLL (-●-) and citrate (-○-) during the precipitation of CaP-pDNA particles on their zeta potential
(b). Data are shown as averages with error bars representing standard deviation.

3.2. In vitro transfection with eGFP using CaP-pDNA

The efficiency of transfection of MC3T3-E1 cells was quantified as the fluorescence
intensity of eGFP expressed by the cells. As shown in Fig.4a, the transfection efficiency of CaPpDNA exceeds that of the commercial transfection agent, jetPRIME at all but the lowest
concentration of pDNA delivered (0.25 μg/well). At 1 and 0.5 μg of pDNA per well, the
transfection efficiency of CaP is at most time points by more than an order of magnitude higher
than that of jetPRIME, showing that CaP outperforms jetPRIME when high loading capacity is
required from the vehicle. In fact, a typical weakness of commercial non-viral carriers is their
limited loading capacity; however, when higher concentrations of the carrier were employed to
cope with this issue in this study, reduced confluency resulted and was directly proportional to
the concentration of the carrier. In contrast, such detrimental effects were not seen in
transfections with CaP-pDNA complexes. The percentage of cells transfected using CaP-pDNA
on day 2 was 37 ± 5 %, lower than 56 ± 12 % for jetPRIME. However, the increased transfection
rate of jetPRIME resulted in lowered cell viability. The number of viable cells on days 2 and 5
was significantly higher in wells containing cells transfected using CaP-pDNA than in those
transfected using jetPRIME (Fig.4b) and there was also no significant decrease in cell viability
compared to the control population following transfection with CaP-pDNA (Fig.4b). Also,
whereas increasing the amount of pDNA complexed with jetPRIME resulted in decreased
transfection rate, the opposite effect was seen for CaP (Fig.4a). Still, a saturation point for
transfection is reached between 0.5 and 1µg of pDNA per well, with larger concentration of
pDNA failing to result in statistically significant increases in the transfection efficiency.
Interestingly, the greater the amount of pDNA, the later the fluorescence intensity peaks: on day
2 when 0.25 μg of pDNA is used, day 3 when 0.5 μg is used, and day 4 when 1 μg is used. In all
cases, the drop in the fluorescence intensity following its peaking between days 2 and 4 is more
gradual than the rise from nanoparticle transfection at day 0. Ca/P molar ratio is another
synthesis parameter that affects the properties of CaP precipitates [32]. Ultrahigh Ca/P molar
ratios are employed to minimize the effects of Ca2+-pDNA complexation on supersaturation, yet
the most optimal Ca/P molar ratio was found to be ~ 170 and was routinely used in CaP-pDNA
transfections [17], [33], [34].The effects of other transfection parameters, including the duration
of nanoparticle incubation and minor changes in precursor solution compositions, are listed in
the supplementary section. Replacing HEPES from HxPO4x-3 to Ca2+ precursor increased the
transfection rate, demonstrating that organic buffers play a more intricate surface or complexing
role than merely maintaining steady pH. This is in agreement with previous reports, including the
one where the use of organic Tris and of inorganic phosphates as buffers led to precipitation of
thoroughly different CaP phases [35]. Eliminating NaCl and precipitating CaP-pDNA at zero
background ionic strength also increased the transfection rate, the reason being the absence of
Na+ ions, potent nucleation inhibitors when it comes to formation of apatite. The absence of Na+
ions lowers the nucleation lag time and speeds up the precipitation of apatite [36], which may
increase the yield and, thus, the transfection capacity of the sol. Drug release from CaP carrier is
known to differ depending on whether the release is assessed in SBF or PBS [37]; likewise, the
interaction between pDNA and CaP is expected to be affected by even the most minor changes in
the ionic strength of the medium. Finally, different cell types transfect with different efficiencies:
e.g., MC3T3-E1 more difficultly than HeLa [33], HEK293 easier than primary lymphocytes
[38]. Here we demonstrate that osteosarcoma K7M2 cells show an almost four times higher
fluorescence intensity than the pre-osteoblastic MC3T3-E1 cells following transfection with CaP
nanoparticles (Fig.4c).

Fig.4. (a) Fluorescence intensity as a measure of the transfection of MC3T3-E1 cells depicted as a function of time
and of different amounts of two different types of gene delivery carriers added per well (i.e., 5 x 104 cells): CaP
synthesized at DS 15 and jetPRIME. (b) Viability of MC3T3-E1 cells transfected using different carriers, including
CaP-pDNA-PLL at 20 ng/μl of PLL and CaP-pDNA-citrate at 10 mM of citrate. The amount of jetPRIME and CaP
was normalized so as to deliver the identical amount of 0.5 μg of pDNA to each well seeded with cells. (c)
Difference in the mean fluorescence intensity as a measure of the transfection of MC3T3-E1 and K7M2 cells on the
3rd day of transfection using CaP-pDNA synthesized at DS 15 and delivering 1 μg pDNA per well. Data are shown
as averages with error bars representing standard deviation.

Supersaturation of the solution precipitating CaP-pDNA was optimized to improve the
transfection rate. To that end, four different precipitates, whose DS of the parent solution ranged
from 12.5 to 21, were compared (Table 1). This range was chosen so as to have the metastable
conditions typical for simulated body fluid on the low DS end and conditions yielding abrupt
precipitation on the high DS end. Interestingly, as DS increases from 12.5 to 15, a multifold
increase in the transfection efficiency occurs (Fig.5). This is partly due to the 3.6 times higher
binding efficiency of pDNA to CaP measured at DS 15 compared to DS 12.5 (Table 1). Further
increases in DS, however, lead to decreased transfection efficiency despite almost complete
binding of pDNA to CaP synthesized in the DS range of 15 - 21. Transfection using the
precipitate yielded at DS 17.5 is, thus, insignificantly higher than that at DS 12.5. Further
increases in DS result in little to no transfection, suggesting the optimality of supersaturation
conditions at DS = 15, the approximate boundary between the metastable and unstable solutions.
The influence of DS on transfection efficiencies can be explained also by morphological
differences. DS 15 yields spherical particles and high transfection rate, whereas DS 17.5 and 21
yield acicular particles and low transfection rates, suggesting that spherical particle morphologies
are more conducive to transfection than anisotropic ones.
Synthesis yield under different DS values and Ca/P ratios increased by 1 and 2 orders of
magnitude as DS increased from 15 to 17.5 and 21, respectively (Table 1). The fact that
transfection using colloids made at DS 15 was with 10 – 100 times lower yield than using those
precipitated at DS 17.5 and 21, and yet was significantly better than using colloids made at any
higher or lower DS indicates that particle morphology is more important than the amount of
carrier. That this effect is not solely due to a difference is pDNA binding efficiency is seen from
Table1: for CaP synthesized at DS 15, pDNA binding efficiency was 93.3 ± 0.6 %, lower than
for those made at DS 17.5 and 21: 99.47 ± 0.92 and 97.07 ± 0.61 %, respectively. Excessive size
can prevent particles from undergoing clathrin- and caveolae-mediated endocytosis [39], but that
this effect is neither due to the size difference is demonstrated by the comparable longest
dimension of particles made under all three DS values > 15.

Fig.5. (a) The effect of the degree of supersaturation (DS) of the solution precipitating CaP-DNA on the efficiency
with which MC3T3-E1 cell line is being transfected using these particles. Data are shown as averages with error
bars representing standard deviation. (b) Live fluorescent imaging of cells glowing in green following transfection
with eGFP using CaP-pDNA prepared at different DS values.

Fig.6. Confocal optical images of MC3T3-E1 cells subjected to a CaP-pDNA nanoparticle treatment (1µg of pDNA
per well) (a) and of transfected MC3T3-E1 cells expressing eGFP (b). The images show CaP-pDNA particles
stained in green, f-actin stained in red, eGFP stained in purple, and the cell nuclei stained in blue.

Confocal optical images of MC3T3-E1 cells transfected by CaP-pDNA are shown in
Fig.6. Intracellular uptake of the particles is required before eGFP plasmid can be released into
the cytosol and transported to the nucleus for the transcription. Fig.8a shows the presence of fine
nanoparticle conglomerates inside the transfected cells, whereas Fig.8b demonstrates the
subsequent expression of the florescent protein.
3.3. In vitro transfection with eGFP using CaP-pDNA-PLL and CaP-pDNA-citrate
The addition of PLL at 4 - 20 ng/μl did not enhance transfection rates in the first four
days following the treatment with CaP-pDNA-PLL nanoparticles. However, after day 4, eGFP
expression was consistently higher compared to PLL-free carriers (Fig.7a). Therefore, the most
obvious effect of PLL is to extend the transfection rate over longer periods of time. This longterm effect of PLL on transfection is shown in Fig.7b where the ratio of fluorescence from eGFP
between days 5 and days 2 displays a steady increase as a function of the concentration of PLL

added to the CaP-pDNA nanoparticle systems. Owing to its intense positive charge, PLL binds
strongly to surfaces and molecules and could hinder the release and unpacking of negatively
charged pDNA [5], delaying the peak of transfection to later time points. Excluding CaP from
the carrier composition and treating cells with PLL-pDNA resulted in no transfection,
demonstrating the essentiality of the role that CaP and its ionic components, predominantly free
Ca2+ ions, play in the gene delivery process.

Fig.7. The effect of the addition of PLL in different concentrations to CaP-DNA particles on the fluorescence of
MC3T3-E1 cell line transfected with GFP using these particles (a) and the ratio between the eGFP fluorescence on
days 5 and 2 as a function of the concentration of PLL in CaP-pDNA-PLL (b). Data are shown as averages with
error bars representing standard deviation.

The addition of citrate at 0.01 – 10 mM increased the transfection efficiency at lower
concentrations (0.01 and 0.1 mM), but dropped it to zero at higher concentrations (1 and 10 mM)
(Fig.8a). As seen from Fig.2b, citrate disperses CaP-pDNA particles only at concentrations
greater or equal to 1 mM, which is the same concentration at and above which no transfection
occurs. This is partly due to low pDNA-CaP binding efficiency at 1mM or higher concentrations
of citrate. As seen from Fig.8b, this binding efficiency drops from 99.07 ± 1.01 % for 0.01 mM
of citrate to 85.73 ± 2.54 % for 0.1 mM and 4.13 ± 6.50 for 1 mM. With the size of a single
DNA plasmid equaling ~ 10 nm (Fig.2a), this means that breaking CaP agglomerates using
citrate anions down to a similar range of sizes (~ 10 nm) obstructs pDNA binding and that
moderate agglomeration of CaP is required for transfection to occur. If CaP particles contact
cells as singlets, endocytosis may not occur. Another possibility is that cell monolayers come
into a lesser contact with CaP-pDNA when the particles are well dispersed and there is no
sedimentation. This effect, where agglomeration of nanoparticles is either required for uptake
[40], [41] or leads to a better uptake compared to fully dispersed systems [42], has been observed
earlier. It suggests that the most potent colloids for transfection are those at the boundary
between the unstable and the metastable ranges. Similar to erythrocytes whose ζ potential of -15
mV [43] places them at one such boundary, making them unstable enough to coagulate around
an open wound, but also stable enough not to spontaneously form a clot, colloids with a high
potential for transfection must be stable enough not to segregate into ineffective flocculates, yet
unstable enough to form sediments and fine agglomerates capable of reaching the cell surface
and be endocytosed. And if local sedimentation of nanoparticles is required for endocytosis, then
perfectly stable colloidal dispersions in transfection would not be that perfect from a practical
standpoint [44]. Poor colloidal stability due to aggregation, often cited as the critical weakness of

CaPs in gene delivery [45], may, in fact, be the key to their excellent performance in this context,
provided that it is controlled to some extent.

Fig.8. The effect of the addition of citrate in different concentrations to CaP-DNA particles on the fluorescence of
MC3T3-E1 cell line transfected with GFP using these particles (a) and pDNA-CaP binding efficiency as a function
of the concentration of citric acid (b). Data are shown as averages with error bars representing standard deviation.

Zeta potential values indicate that citrate disperses CaP-pDNA particles and does not
replace DNA from the surface of CaP. Specifically, while citrate produced no significant change
in zeta potential of CaP-pDNA, it decreased the zeta potential of pure CaP while retaining its
positive value (+ 2 mV at ≥ 1 mM). Interestingly, when 1 mM citrate is added to CaP-pDNA sol
following precipitation, transfection is still noticeable, unlike in the case when citrate is present
during precipitation of CaP-pDNA. The reason is that post-precipitation addition of citrate does
not disperse CaP-DNA particles as much as when the anion is present in the solution during
precipitation. Also, the transfection efficiency was better at the lowest concentration of citrate
(0.01 mM) than at the highest one (0.1 mM) for which this augmentation effect was observed.
This further indicates that moderate, not complete de-agglomeration is needed to maximize the
efficiency of transfection using CaP-pDNA. As seen in Fig.8a, the curve of the function of the
transfection rate vs. time maintains the same shape, reaching the maximum at day 4, and is only
shifted to higher values as transfection is improved at 0.01 and 0.1 mM of citrate. The ratio
between eGFP fluorescence on days 5 and 2 remains constant as the concentration of citrate is
increased. This is unlike the effect PLL had on the change of the transfection rate with time
(Fig.7). Transfection with citrate had a higher ratio of transfection on day 5 and day 2 than that
with PLL, but was unaffected by concentration. Immunofluorescent images show the timeline of
transfection events, from endocytosis of CaP-citrate and CaP-PLL carriers to the onset of eGFP
expression to the complete pervasion of the transfected cells with the fluorescent signal (Figs.910). Finally, while the addition of PLL did not significantly decrease cell viability, the addition
of citrate did, though only on day 2; by day 5, cell viability recovered and was equal to control
populations (Fig.4b). Citric acid has been previously reported not to be toxic to MC3T3-E1 cells
[46]. Therefore, one possibility is that greater transfection enabled by the citrate anion results in
moderate, short-term cytotoxicity from which cells fully recover (Fig.4b) because excessive
penetration of DNA into the cell can cause its accumulation in cell membrane and organelles
other than nucleus [47] where it may exert a toxic and apoptotic effect on the cell [48]. The
decrease in viability may also be due to the augmented differentiation of MC3T3-E1 cells into an
osteoblastic phenotype and a corresponding decrease in the proliferation rate [46] in case citric

acid plays a similar role as that of ascorbic acid in promoting the differentiation of this particular
cell line. This is especially so since osteoblasts are known to express citric acid [49], an essential
component of bone microarchitecture.

Fig.9. Confocal optical images of MC3T3-E1 cells subjected to a CaP-pDNA-citrate nanoparticle treatment (1µg of
pDNA per well) showing the timeline of transfection events: (a) CaP particles (green) are endocytosed and are seen
in the vicinity of the nucleus (blue), at which stage they have already delivered their plasmid payload; (b) MC3T3E1 cells are now transfected and the expression of eGFP (purple) has begun; (c) the expression of eGFP within the
transfected MC3T3-E1 cells is now at its maximum and the transfected cells glow throughout their entire volume.
The images show CaP-pDNA particles stained in green, f-actin stained in red, eGFP stained in purple and the cell
nuclei stained in blue.

Fig.10. Confocal optical images showing the intracellularly located CaP-PLL carriers (green) delivering eGFP
plasmid (extranuclear blue) to MC3T3-E1 cell nuclei (blue) through the cytoplasmic (red – f-actin cytoskeletal
microfilaments).

Conclusion
Owing to their variety of appealing properties, ranging from the high capacity for
adsorption of nucleic acids to the ability to launch endosomal escape of plasmids to exceptional
biocompatibility and bioresorbability, CaP nanoparticles are considered a viable non-viral gene
delivery carrier. However, although CaP was first used as a non-viral vector for gene delivery in
1973[50], insufficient effort has been made since then to optimize its properties for more
efficient and consistent transfection. Especially in the last two decades there has been little
success in enhancing the efficacy of CaP for this therapeutic application. Although much work

has been done to optimize the transfection process [18][35][53]–[55], there is still a vast room
for improvement. One of the central limitations is the aggregation propensity of CaP
nanoparticles and their low colloidal stability. This difficulty in controlling the particle size using
the basic principles of colloid chemistry is a major weak point that disfavors the use of CaP as a
transfection agent. It is also thought that the low efficacy with which non-viral vectors enter the
cell is the reason why viral vectors still retain the advantage over their non-viral counterparts,
including CaP. If the passage across the cell membrane could be improved through precise
optimization of CaP nanoparticle properties, it is hoped that the corresponding gene delivery
efficacy could be made comparable to that of viral vectors, circumventing at the same time an
array of risks and side effects associated with the use of viral agents.
Here we report on the optimization of some of the properties of CaP nanoparticles as
colloidal gene carriers by varying selected precipitation and transfection conditions and
investigating the effects of two separate additives, citric acid and PLL. As indicated by the DLS
analysis, both citrate anion and PLL, along with pDNA, were localized within the hydrodynamic
shear plane of CaP nanoparticles. CaP precipitation conditions, including supersaturation ratio,
Ca/P molar ratio, ionic strength and other compositional parameters that defined the precursor
solutions, all affected transfection in different ways. The same can be said for the variations in
the transfection conditions, mainly the concentration of the carrier and of the genomic load,
alongside the timescale of the treatment. Susceptibility to changes in properties depending on
this plethora of conditions allowed for the optimization of CaP nanoparticles for a superior
transfection compared to a commercial reagent, in terms of efficiency, cell viability and dosage
flexibility. Plasmid DNA was also shown to act as a promoter of nucleation of CaP. Spherical
CaP particle morphologies were more conducive to transfection than the anisotropic ones, while
moderate agglomeration of CaP particles positively affected pDNA binding and the overall
transfection process. Both types of surface additives, citrate and PLL, exerted positive effects on
transfection when their concentrations were precisely optimized: while citrate enhanced
transfection when added at low concentrations, PLL extended it over longer periods of time. The
exploration of synergy between the two additives will be the subject of further studies.
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